TY - JOUR T1 - Distinct age-specific SARS-CoV-2 IgG decay kinetics following natural infection JF - medRxiv DO - 10.1101/2021.08.05.21259465 SP - 2021.08.05.21259465 AU - Calvin P Sjaarda AU - Emily Moslinger AU - Kyla Tozer AU - Robert I. Colautti AU - Samira Kheitan AU - Robyn Meurant AU - Stefanie Van Cleaf AU - Ali Ardakani AU - Oliver Bosnjak AU - Abdi Ghaffari AU - Prameet M Sheth Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/08/07/2021.08.05.21259465.abstract N2 - Background Antibody responses to SARS-CoV-2 can be observed as early as 14 days post-infection, but little is known about the stability of antibody levels over time. Here we evaluate the long-term stability of anti-SARS-CoV-2 IgG antibodies following infection with SARS-CoV-2 in 402 adult donors.Methods We performed a multi-center study carried out at Plasma Donor Centers in the city of Heidelberg (Plasmazentrum Heidelberg, Germany) and Munich (Plasmazentrum München, Germany). We present anti-S/N and anti-N IgG antibody levels in prospective serum samples collected up to 403 days post recovery from SARS-CoV-2 infected individuals.Results The cohort includes 402 adult donors (185 female, 217 male; 17 - 68 years of age) where anti-SARS-CoV-2 IgG levels were measured in plasma samples collected between 18- and 403-days post SARS-CoV-2 infection. A linear mixed effects model demonstrated IgG decay rates that decrease over time (χ2=176.8, p<0.00001) and an interaction of time*age χ (χ2=10.0, p<0.005)), with those over 60+ years showing the highest baseline IgG levels and the fastest rate of IgG decay. Baseline viral neutralization assays demonstrated that serum IgG levels correlated with in vitro neutralization capacity in 91% of our cohort.Conclusion Long-term antibody levels and age-specific antibody decay rates suggest the potential need for age-specific vaccine booster guidelines to ensure long term vaccine protection against SARS-CoV-2 infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding: The data collection and study was funded by Biomex GmbH, Heidelberg, Germany and Novateur Ventures Inc., Vancouver, Canada.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All donors provided informed consent and had to meet the German Medical Association criteria for blood and blood component collection according to the transfusion and hemotherapy guidelines. All experimental protocols were approved by and conducted in accordance with the Ethics Commission of the Bavarian State Medical Association (No 05142).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the main text or the supplementary materials. The data analysis pipeline is available at https://github.com/CalvinSjaarda/COVID_immune_IgG.git. ER -